Plan B ® One-Step is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse. Plan B One-Step is available only by prescription for women younger than age 17 years, and available over the counter for women 1...
Take Plan B One-Step orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. Plan B One-Step can be used at any time during the menstrual cycle. If vomiting occurs within two hours of taking the tablet, consideration should be given to repeating the dose.
The Plan B One-Step (levonorgestrel) tablet 1.5 mg is available in a PVC/aluminum foil blister package. The tablet is almost white, round, and marked G00 on one side. NDC 21695-973-01 (1 tablet unit of use package) Store Plan B One-Step at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].
www.fda.gov/medwatch
www.PlanBOneStep.comPlan B® One-Step is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse.
Plan B One-Step is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older.
Plan B One-Step is not indicated for routine use as a contraceptive.
Take Plan B One-Step orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. Plan B One-Step can be used at any time during the menstrual cycle.
If vomiting occurs within two hours of taking the tablet, consideration should be given to repeating the dose.
The Plan B One-Step tablet is supplied as an almost white, round tablet containing 1.5 mg of levonorgestrel and is marked G00 on one side.
Plan B One-Step is contraindicated for use in the case of known or suspected pregnancy.
Ectopic pregnancies account for approximately 2% of all reported pregnancies. Up to 10% of pregnancies reported in clinical studies of routine use of progestin-only contraceptives are ectopic.
A history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. Healthcare providers, however, should consider the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain after taking Plan B One-Step. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking Plan B One-Step.
Plan B One-Step is not effective in terminating an existing pregnancy.
Some women may experience spotting a few days after taking Plan B One-Step. Menstrual bleeding patterns are often irregular among women using progestin-only oral contraceptives and women using levonorgestrel for postcoital and emergency contraception.
If there is a delay in the onset of expected menses beyond 1 week, consider the possibility of pregnancy.
Plan B One-Step does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).
A physical examination is not required prior to prescribing Plan B One-Step. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking Plan B One-Step.
A rapid return of fertility is likely following treatment with Plan B One-Step for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of Plan B One-Step to ensure ongoing prevention of pregnancy.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Plan B One-Step was studied in a randomized, double-blinded multicenter clinical trial. In this study, all women who had received at least one dose of study medication were included in the safety analysis: 1,379 women in the Plan B One-Step group, and 1,377 women in the Plan B group (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). The mean age of women given Plan B One-Step was 27 years. The racial demographic of those enrolled was 54% Chinese, 12% Other Asian or Black, and 34% were Caucasian in each treatment group. 1.6% of women in the Plan B One-Step group and 1.4% in Plan B group were lost to follow-up.
The most common adverse events (>10%) in the clinical trial for women receiving Plan B One-Step included heavier menstrual bleeding (30.9%), nausea (13.7%), lower abdominal pain (13.3%), fatigue (13.3%), and headache (10.3%). Table 1 lists those adverse events that were reported in > 4% of Plan B One-Step users.
Most Common Adverse Events (MedDRA) | Plan B One-Step N = 1359 (%) |
| Heavier menstrual bleeding | 30.9 |
| Nausea | 13.7 |
| Lower abdominal pain | 13.3 |
| Fatigue | 13.3 |
| Headache | 10.3 |
| Dizziness | 9.6 |
| Breast tenderness | 8.2 |
| Delay of menses (> 7 days) | 4.5 |
The following adverse reactions have been identified during post-approval use of Plan B (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal Disorders
Abdominal Pain, Nausea, Vomiting
General Disorders and Administration Site Conditions
Fatigue
Nervous System Disorders
Dizziness, Headache
Reproductive System and Breast Disorders
Dysmenorrhea, Irregular Menstruation, Oligomenorrhea, Pelvic Pain
Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the plasma concentrations of progestins, and may decrease the effectiveness of progestin-only pills. Some drugs or herbal products that may decrease the effectiveness of progestin-only pills include:
Significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of co-administration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.
Consult the labeling of all concurrently used drugs to obtain further information about interactions with progestin-only pills or the potential for enzyme alterations.
Many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects.
In general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the health, growth, or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers taking progestin-only pills for long-term contraception, resulting in detectable steroid levels in infant plasma.
Safety and efficacy of progestin-only pills for long-term contraception have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of Plan B One-Step emergency contraception before menarche is not indicated.
This product is not intended for use in postmenopausal women.
No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both Plan B and the Yuzpe regimen (another form of emergency contraception). There was a non-statistically significant increased rate of pregnancy among Chinese women in the Plan B One-Step trial. The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown.
No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of Plan B One-Step.
No formal studies were conducted to evaluate the effect of renal disease on the disposition of Plan B One-Step.
Levonorgestrel is not a controlled substance. There is no information about dependence associated with the use of Plan B One-Step.
There are no data on overdosage of Plan B One-Step, although the common adverse event of nausea and associated vomiting may be anticipated.
The Plan B One-Step tablet contains 1.5 mg of a single active steroid ingredient, levonorgestrel [18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-, (17 α)-(-)-], a totally synthetic progestogen. The inactive ingredients are colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, potato starch, and talc.
Levonorgestrel has a molecular weight of 312.45, and the following structural and molecular formulas:
Emergency contraceptive pills are not effective if a woman is already pregnant. Plan B One-Step is believed to act as an emergency contraceptive principally by preventing ovulation or fertilization (by altering tubal transport of sperm and/or ova). In addition, it may inhibit implantation (by altering the endometrium). It is not effective once the process of implantation has begun.
Absorption
Following a single dose administration of Plan B One-Step in 30 women under fasting conditions, maximum plasma concentrations of levonorgestrel of 19.1 ng/mL were reached at 1.7 hours. See Table 2.
| Mean (± SD) | |||||
| Cmax (ng/mL) | AUCt (ng·hr/mL)* | AUCinf (ng·hr/mL)* | Tmax (hr)† | t1/2 (hr) | |
| Levonorgestrel | 19.1 ( 9.7) | 294.8 ( 208.8) | 307.5 ( 218.5) | 1.7 (1.0-4.0) | 27.5 ( 5.6) |
Cmax = maximum concentration | |||||
Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of Plan B One-Step has not been evaluated.
Distribution
The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg. It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.
Metabolism
Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.
Excretion
About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.
Specific Populations
Pediatric
This product is not intended for use in the premenarcheal population, and pharmacokinetic data are not available for this population.
Geriatric
This product is not intended for use in postmenopausal women, and pharmacokinetic data are not available for this population.
Race
No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both Plan B and the Yuzpe regimen (another form of emergency contraception). There was a non-statistically significant increased rate of pregnancy among Chinese women in the Plan B One-Step trial. The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].
Hepatic Impairment
No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of Plan B One-Step.
Renal Impairment
No formal studies were conducted to evaluate the effect of renal disease on the disposition of Plan B One-Step.
Drug-Drug Interactions
No formal drug-drug interaction studies were conducted with Plan B One-Step [see DRUG INTERACTIONS (7)].
Carcinogenicity: There is no evidence of increased risk of cancer with short-term use of progestins. There was no increase in tumorgenicity following administration of levonorgestrel to rats for 2 years at approximately 5 µg/day, to dogs for 7 years at up to 0.125 mg/kg/day, or to rhesus monkeys for 10 years at up to 250 µg/kg/day. In another 7 year dog study, administration of levonorgestrel at 0.5 mg/kg/day did increase the number of mammary adenomas in treated dogs compared to controls. There were no malignancies.
Genotoxicity: Levonorgestrel was not found to be mutagenic or genotoxic in the Ames Assay, in vitro mammalian culture assays utilizing mouse lymphoma cells and Chinese hamster ovary cells, and in an in vivo micronucleus assay in mice.
Fertility: There are no irreversible effects on fertility following cessation of exposures to levonorgestrel or progestins in general.
A double-blind, randomized, multicenter, multinational study evaluated and compared the efficacy and safety of three different regimens for emergency contraception. Subjects were enrolled at 15 sites in 10 countries; the racial/ethnic characteristics of the study population overall were 54% Chinese, 34% Caucasian, and 12% Black or Asian (other than Chinese). 2,381 healthy women with a mean age of 27 years, who needed emergency contraception within 72 hours of unprotected intercourse were involved and randomly allocated into one of the two levonorgestrel groups. A single dose of 1.5 mg of levonorgestrel (Plan B One-Step) was administered to women allocated into group 1. Two doses of 0.75 mg levonorgestrel 12 hours apart (Plan B) were administered to women in group 2. In the Plan B One-Step group, 16 pregnancies occurred in 1,198 women and in the Plan B group, 20 pregnancies occurred in 1,183 women. The number of pregnancies expected in each group was calculated based on the timing of intercourse with regard to each woman’s menstrual cycle. Among women receiving Plan B One-Step, 84% of expected pregnancies were prevented and among those women taking Plan B, 79% of expected pregnancies were prevented. The expected pregnancy rate of 8% (with no contraceptive use) was reduced to approximately 1% with Plan B One-Step.
Emergency contraceptives are not as effective as routine contraception since their failure rate, while low based on a single use, would accumulate over time with repeated use [see INDICATIONS AND USAGE (1)].
In the clinical study, bleeding disturbances were the most common adverse event reported after taking the levonorgestrel-containing regimens. More than half of the women had menses within two days of the expected time; however, 31% of women experienced change in their bleeding pattern during the study period; 4.5% of women had menses more than 7 days after the expected time.
The Plan B One-Step (levonorgestrel) tablet 1.5 mg is available in a PVC/aluminum foil blister package. The tablet is almost white, round, and marked G00 on one side.
NDC 21695-973-01 (1 tablet unit of use package)
Store Plan B One-Step at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].
Mfg. by Gedeon Richter, Ltd., Budapest, Hungary
for Duramed Pharmaceuticals, Inc.
Subsidiary of Barr Pharmaceuticals, Inc.
Pomona, New York 10970
Phone: 1-800-330-1271
Website: www.PlanBOneStep.com
Revised: August 2009
11001524
Relabeled by:
Rebel Distributors Corp
Thousand Oaks, CA 91320
FOR CLINIC USE ONLY. NOT FOR RESALE.
NDC 21695-973-01
Plan B
One-Step®
(levonorgestrel) tablet, 1.5 mg
Emergency Contraceptive
Reduces the chance of pregnancy after unprotected sex (if a regular birth control method fails or after sex without birth control)
Not for regular birth control.
Rx only for women
younger than age 17
One Tablet
One Dose
•Take as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it, the better Plan B One-Step® will work.
1 Tablet Levonorgestrel 1.5mg
•Not for regular birth control.
Plan B One-Step® should be used only in emergencies.
•Does not protect against HIV/AIDS or other STDs.
Drug Facts
Active ingredient Purpose
Levonorgestrel 1.5mg........................Emergency contraceptive
Use reduces chance of pregnancy after unprotected sex
(if a contraceptive failed or if you did not use birth control)
Warnings
Allergy alert: Do not use if you have ever had an allergic reaction to levonorgestrel
Sexually transmitted diseases (STDs) alert: This product does not protect against HIV/AIDS or other STDs
Do not use
■ if you are already pregnant (because it will not work)
■ for regular birth control
When using this product you may have
■ menstrual changes
■ nausea
■ lower stomach (abdominal) pain
■ tiredness
■ headache
■ dizziness
■ breast pain
■ vomiting
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control center right away.
Directions
■ women 17 years of age or older:
■ take tablet as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it the better it will work.
■ if you vomit within 2 hours of taking the medication, call a healthcare professional to find out if you should repeat the dose
■ prescription only for women younger than age 17. If you are younger than age 17, see a healthcare professional.
Other information
■ before using this product read the enclosed consumer information leaflet for complete directions and information
■ this product is not recommended for regular birth control. It does not work as well as most other birth control methods used correctly.
■ this product works mainly by preventing ovulation (egg release). It may also prevent fertilization of a released egg (joining of sperm and egg) or attachment of a fertilized egg to the uterus (implantation).
■ when used correctly every time you have sex, latex condoms greatly reduce, but do not eliminate, the risk of pregnancy and the risk of catching or spreading HIV, the virus that causes AIDS. See condom labeling for additional STD information.
■ tablet is enclosed in a blister seal. Do not use if the blister seal is broken.
■ store at 20-25°C (68-77°F)
Inactive ingredients
colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, potato starch, talc
Questions or comments?
For more information or to speak to a healthcare professional,
call 1-800-330-1271, 24 hours a day/7 days a week.
Visit our Web site at www.planbonestep.com
| Class | Version | Type | Effective |
|---|---|---|---|
| LEVONORGESTREL Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20230718 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 21695-973-01 | 2019-09-24 | C162847 | 48780-1 | 934fe258-4a55-48b1-e053-8cdaa90a720a | These highlights do not include all the information needed to use Plan B One-Step safely and effectively. See full prescribing information for Plan B One-Step. Plan B One-Step (levonorgestrel) tablet, 1.5 mg, for oral use Initial U.S. Approval: 1982 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 21695-973-01 | Plan B One-Step | 1 in 1 CARTON | TABLET | 1 | 1 | |
| 21695-973-01 | Plan B One-Step | 1 in 1 BLISTER PACK | TABLET | 1 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 21695-973-01 | EA - Each | 21695-973 | c88f08c8-6164-4c43-a384-a62255ed27c4 | 1 | 2012-07-24 |
| 51285-942-88 | EA - Each | 51285-942 | 8f9cc747-d81c-442b-93b9-3cff5cffeea4 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LEVONORGESTREL | ACTIVE INGREDIENT | 5W7SIA7YZW | 1 | |
| LEVONORGESTREL | ACTIVE MOIETY | 5W7SIA7YZW | 1 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 | |
| STARCH, POTATO | INACTIVE INGREDIENT | 8I089SAH3T | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 21695-973 | 21695-973-01 |
| 51285-942 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| STARCH, POTATO | 8I089SAH3T | IACT |
| TALC | 7SEV7J4R1U | IACT |
| LEVONORGESTREL | 5W7SIA7YZW | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 60 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | 174 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / INTRAVENOUS | 900 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE / ORAL | 5785 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, CHEWABLE / ORAL | 180 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 18 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | POWDER, FOR SUSPENSION / ORAL | 34 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION / ORAL | 900 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, ORALLY DISINTEGRATING / ORAL | 366 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 47.5 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE, EXTENDED RELEASE / ORAL | 194 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 21 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / BUCCAL | 43 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INSERT / VAGINAL | 2282 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CONCENTRATE / ORAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE, DELAYED RELEASE / ORAL | 216 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FOR SUSPENSION / ORAL | 2794 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| TALC | TALC | 7SEV7J4R1U | ELIXIR / ORAL | 4.5 mg/5ml | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 107 mg | ||
| TALC | TALC | 7SEV7J4R1U | PELLET / ORAL | 69 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION/ DROPS / ORAL | 90 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 214 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING / ORAL | 100 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, COATED / ORAL | 1301 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, DELAYED RELEASE / ORAL | 713 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / SUBCUTANEOUS | 98 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 690 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / RECTAL | 32.4 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, COATED PELLETS / ORAL | 14 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, SUGAR COATED / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SOLUTION / ORAL | 1.8 mg/120ml | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, DELAYED RELEASE / ORAL | 2313 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE / ORAL | 8946 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021998-001 | PLAN B ONE-STEP | LEVONORGESTREL | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N021998-001 | PLAN B ONE-STEP | 1.5MG | TABLET / ORAL | RLD, RS | 2009-07-10 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e17b3ec0-7739-4775-b7a2-a262f4f3a836 | e17b3ec0-7739-4775-b7a2-a262f4f3a836 | 2011-09-13 | Warnings, Adverse reactions | e17b3ec0-7739-4775-b7a2-a262f4f3a836 e17b3ec0-7739-4775-b7a2-a262f4f3a836 |
Adverse event summaries are temporarily unavailable. Other product information remains available.